Back to Tim Ferriss

Reimagining Biotech with Jake Becraft of Strand Therapeutics — Tim’s Founder Kitchen

Tim FerrissJune 2, 20262h 6m
Topics73
China vs. United States Clinical Trial Infrastructure0:00What Strand Therapeutics Does0:30How Jake Becraft and Tim Met3:00Why Tim Became Interested in Strand3:30The Patient Image from the ASCO Poster6:00Impact on One Patient9:00Kaplan-Meier Curve and Investor Resonance10:00Good Drug vs. Good Product12:30Treatment Description for the Patient in the Photographs15:00The Abscopal Response20:00Product Perspective Limitations and Infrastructure23:30The Challenge of Systemic Genetic Medicine Delivery25:44The Three Hidden Problems Behind the Delivery Challenge27:01First Principles Thinking and Strand's Founding Vision28:01The Impending Revolution in Genetic Medicine29:45The Infrastructure Gap and Future of Healthcare31:20Building the Instruction Manual for Future Therapies32:30Expanding Applications Beyond Cancer33:15Identifying Key Stakeholders for the Message34:45The Shift to Personalized, Variant-Based Medicine36:00Historical Precedent for Policy Collaboration37:20The Need for a Biotechnology AI Report38:45Communication Strategy for Policy Makers39:45Why Good Drugs Die and the Delivery Problem42:00Reframing the Delivery Discussion43:15Engaging Policy Makers on Breakthrough vs. Incremental Innovation44:45The Economics of Medicine as Preventative Care47:00Aligning Incentives with Policy Makers48:30Regulatory Reform to Accelerate Drug Development49:46The IND Process and Its Costs52:01Consequences of the Current System53:30Proposed Clinical Trial Notification System55:30Global Competition and Implementation Feasibility57:31Geographic Concentration of Biotechnology Innovation1:00:30Likelihood of Regulatory Change1:02:00International Collaboration on Clinical Trials1:05:31Resource Constraints and Partnership Strategy1:06:01Platform Strategy and Definitions1:09:00Framing the Washington Post Op-Ed1:13:12Refining the Message with Split Testing1:14:00Congressional Hearing and Reframing1:15:00Presidential Policy Objectives1:16:30Split Testing Headlines with Pikfu1:17:00Simplifying Messages for Policymakers1:19:00Current Status of Messaging Efforts1:20:00Lessons from DC Engagement1:22:00The Principle of Making People Care1:23:00Documents Shared for Review1:25:00Using Split Test Results for Sharing1:27:00Working on RNA Medicine and Platform Therapeutics1:28:00Comparing Biotech to the Rocket Industry1:29:00Defining Platform Therapeutics1:30:30Moderna's mRNA Platform as an Example1:33:30Two Critical Buckets for Future Medicine1:35:00The Protein Delivery Bottleneck1:37:00Capital Formation and Structural Blockers in Biotech1:38:39The SpaceX Moment for Medicine1:40:30Capital Formation Challenges in Deep Tech1:42:01Long-Term Vision and Capital Partners1:43:33Lessons from NASA, SpaceX, and Amazon1:44:31Public Communication and Mission Discipline1:49:31Post-Conviction, Pre-Consensus Moments1:52:00Alternative Historical Analogies and the Birth of Biotech1:53:31Industry Consolidation and Capital Market Distortion1:55:31Risks of Being a Little Brother to Pharma1:57:32Platform Thinking and Historical Parallels1:58:31Apple as Delivery Platform Example1:59:32Medicine Delivery Vision2:03:30Future Trajectory of mRNA Medicines2:03:37Economics of Personalized Medicine2:04:00Baby KJ Case Study2:04:31CRISPR Limitations and Future Outlook2:05:30Closing Remarks2:06:01
In a Nutshell

Strand Therapeutics is building programmable mRNA medicines that reprogram tumors or immune cells in vivo to trigger immune responses, moving beyond liver-only delivery and direct tumor injection toward systemic, plug-and-play treatment. The core bottleneck is not discovering therapeutic proteins but solving potency, specificity, and delivery to make these therapies scalable products that fit existing infusion infrastructure rather than bespoke, ultra-expensive manufacturing. Jake Becraft argues the US is losing ground to China’s fast clinical trial system and must reform its IND process—shifting initial oversight to certified hospital IRBs like Australia’s CTN model—to cut costs, speed first-in-human testing, and keep biomedical innovation and capital from flowing overseas.

AI-Generated Notes

These notes were generated by AI and may contain inaccuracies.

The United States is massively losing to China in clinical trial infrastructure. China has built an industrialized version of clinical trial infrastructure for first-in-human trials that is so efficient and massively quick that they are able to go faster and cheaper into the thing that matters most, which is first-in-human trials. What started as a place for American companies to come run clinical trials to get data and then take it to the FDA and then do larger trials in the United States has now created a flywheel structure within China where now just Chinese companies run their clinical trials faster than the American companies and then bring their Chinese discovered drugs to the United States. The capital flow and risk capital then says these companies are more efficient and will fund these sorts of aspects.

Strand designs what are called next generation genetic medicines. You have DNA inside of your cells. The DNA makes RNA copies of itself and then that RNA makes proteins. Life is all proteins. Your skin, your hair, your organs, every cell is basically just proteins stacked together. That is everything that we are. You do not really see the DNA and the RNA. It is very small. The protein is what we think of as like our being. The way to actually intervene in disease and get to its core is to create the correct proteins. If you have a deficiency, everything from an enzyme problem to a rare disease to cystic fibrosis, it is usually a problem with a protein that is being incorrectly made by a cell. Over decades, what has gone wrong with that protein and what would need to go right to fix that protein or how you would replace that protein correctly has been figured out. What has not been figured out is how to make the cells do that because it is a very complicated problem to tell certain cells in the body to do various different things.

Sign in to read the full notes

Get access to AI-generated notes, topic timestamps, and more.